Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Therapy Area topics
Cardiovascular
Medtronic bows to the inevitable
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
Medtronic’s Hugo still a long way from victor
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
The future of renal denervation
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
Central Nervous System
The next wave of amyloid-targeting projects approaches
Acumen is the latest player to take aim at amyloid, but competition is fierce.
Aduhelm approval amplifies amyloid assays
Biogen needs blood tests for amyloid beta to progress quickly – and several are in the pipeline.
Biogen and the social contract
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
Diabetes
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Lilly leads the big pharma pack on pipeline value
Huge hopes for diabetes and Alzheimer’s projects swell Lilly’s pipeline valuation, with Glaxosmithkline and Abbvie looking bare in comparison.
Digital Health
Google gears up to launch its first medical device
But with Derm Assist available free, how will the company make money?
Oncology
EHA 2021 movers – more fallers than risers
Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.
Arcus nears crunch time for Gilead opt-in
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
Respiratory
Vertex’s second try at a rare lung disorder
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Various
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.